Healio

Omega-3 supplement fails to improve dry eye symptoms linked to MGD

Please provide your email address to receive an email when new articles are posted on . The mean OSDI change from baseline was –20.5 and –22.7 at 6 and 12 weeks in the omega-3 group vs. –15.1 and ...
Morningstar

Sight Sciences Announces the Results of a Cost-Utility Analysis Demonstrating Cost Savings and Greater Health Utility with the TearCare® System Compared to Cyclosporine 0.05% ...

The Company’s TearCare ® System is 510 (k) cleared in the United States for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland disease ...
Seeking Alpha

Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over ...

MENLO PARK, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Sight Sciences (SGHT), Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology ...
The American Journal of Managed Care

Personalized Management of Dry Eye Disease: From Pathophysiologic Mechanisms to Targeted Therapeutic Approaches

Dry eye disease (DED) is a prevalent, chronic condition diagnosed in about 16.4 million Americans, with an additional 6 million undiagnosed patients experiencing dry eye symptoms. 1 The prevalence of ...